secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2024-02-13T23:59:59+00:00
Accession:  0001517022-24-000019
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Akebia extends separation dates for COO Dahan to June 28 and CLO Hadas to June 14
--------------------------------------------------------------------------------

- COO Michel Dahan's separation extended from March 22 to June 28, 2024.
- SVP/Chief Legal Officer Nicole Hadas separation extended from March 29 to June 14, 2024.
- Both amendments signed on February 8, 2024; earlier retention agreements dated May 5, 2022.
- Separations may further extend to Sept 22, 2024 upon certain specified events.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702224000019/0001517022-24-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702224000019/akba-20240208.htm
  HTML page:      https://secwatch.observer/filing/0001517022-24-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer